Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for treatment of heart failure and critical limb ischemia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/16/12 | $22,200,000 | Series B |
Early Stage Partners Fletcher Spaght Ventures Glengary Global Cardiovascular Innovation Center New Science Ventures Takeda Ventures Tri-State Growth Capital Fund Triathlon Medical Ventures Venture Investors | undisclosed |
| 05/12/15 | $13,500,000 | Series B-2 |
Green Cross POSCO Venture Capital | undisclosed |
